Combination of Novel Therapies for CKD Comorbid Depression
Phase 2
201
about 6.5 years
18+
4 sites in NY, TX, WA
About this study
This trial is testing if combining behavioral therapy, bupropion, and clinical management with a treatment improves outcomes in people with chronic kidney disease (CKD) who also have depression. The goal is to find better ways to treat depression in this specific patient population.
Based on ClinicalTrials.gov records.
What participants do
- 1.Clinical Management
- 2.Participate in Behavioral activation therapy
- 3.Take Bupropion
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bupropion
Secondary: Fatigue assessed by the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scale, High sensitivity C-reactive protein, Serious adverse events, Serious adverse events with monotherapy, Sleep assessed by the Insomnia Severity Index (ISI)
Psychiatry / Mental Health, Renal